A number of research firms have changed their ratings and price targets for Cryolife (NYSE: CRY):
- 5/15/2019 – Cryolife was downgraded by analysts at ValuEngine from a “strong-buy” rating to a “buy” rating.
- 5/12/2019 – Cryolife had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
- 5/1/2019 – Cryolife had its “hold” rating reaffirmed by analysts at Needham & Company LLC.
- 5/1/2019 – Cryolife had its “buy” rating reaffirmed by analysts at Canaccord Genuity. They now have a $35.00 price target on the stock, up previously from $32.00.
- 5/1/2019 – Cryolife was upgraded by analysts at TheStreet from a “c” rating to a “b-” rating.
- 4/23/2019 – Cryolife was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “CryoLife, Inc. is a leader in medical device manufacturing and distribution and in the processing and distribution of implantable living human tissues for use in cardiac and vascular surgeries. It operates throughout the U.S. and internationally. CryoLife manufactures and distributes BioGlue Surgical Adhesive, an FDA-approved adjunct to sutures and staples for use in adult patients in open surgical repair of large vessels. BioGlue is also CE marked in Europe for use in soft tissue repair and has received additional marketing approvals in several other countries throughout the world. CryoLife’s BioFoam Surgical Matrix is CE marked in Europe for use as an adjunct to hemostasis in cardiovascular surgery and on abdominal parenchymal tissues (liver and spleen) when control of bleeding by ligature or conventional methods is ineffective or impractical. CryoLife distributes PerClot, a powdered hemostat, in Europe and other select international countries. “
NYSE:CRY opened at $30.02 on Thursday. The firm has a market cap of $1.12 billion, a P/E ratio of 115.46 and a beta of 0.54. Cryolife Inc has a 52-week low of $23.99 and a 52-week high of $36.05. The company has a debt-to-equity ratio of 0.86, a current ratio of 4.90 and a quick ratio of 3.69.
Cryolife (NYSE:CRY) last posted its quarterly earnings data on Tuesday, April 30th. The medical equipment provider reported $0.04 earnings per share (EPS) for the quarter, meeting the Thomson Reuters’ consensus estimate of $0.04. The company had revenue of $67.50 million during the quarter, compared to analyst estimates of $66.37 million. Cryolife had a positive return on equity of 3.79% and a negative net margin of 0.09%. The firm’s quarterly revenue was up 9.0% on a year-over-year basis. During the same quarter last year, the company earned $0.02 earnings per share. Equities research analysts anticipate that Cryolife Inc will post 0.31 EPS for the current year.
In other Cryolife news, Director Ronald D. Mccall sold 6,200 shares of Cryolife stock in a transaction dated Thursday, February 21st. The stock was sold at an average price of $29.26, for a total transaction of $181,412.00. Following the completion of the sale, the director now owns 137,699 shares of the company’s stock, valued at $4,029,072.74. The sale was disclosed in a filing with the SEC, which is available at the SEC website. Also, VP Amy Horton sold 6,666 shares of Cryolife stock in a transaction dated Wednesday, March 6th. The stock was sold at an average price of $29.15, for a total value of $194,313.90. Following the sale, the vice president now directly owns 103,713 shares of the company’s stock, valued at approximately $3,023,233.95. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 106,775 shares of company stock valued at $3,325,151. Corporate insiders own 4.40% of the company’s stock.
A number of hedge funds have recently modified their holdings of the business. Perceptive Advisors LLC bought a new stake in Cryolife during the first quarter worth about $1,459,000. Schonfeld Strategic Advisors LLC bought a new stake in Cryolife during the first quarter worth about $7,086,000. Metropolitan Life Insurance Co NY lifted its stake in Cryolife by 30.6% during the first quarter. Metropolitan Life Insurance Co NY now owns 14,428 shares of the medical equipment provider’s stock worth $2,320,000 after purchasing an additional 3,379 shares during the last quarter. Advisors Asset Management Inc. lifted its stake in Cryolife by 75.1% during the first quarter. Advisors Asset Management Inc. now owns 1,965 shares of the medical equipment provider’s stock worth $57,000 after purchasing an additional 843 shares during the last quarter. Finally, ArrowMark Colorado Holdings LLC lifted its stake in Cryolife by 8.8% during the first quarter. ArrowMark Colorado Holdings LLC now owns 553,254 shares of the medical equipment provider’s stock worth $16,138,000 after purchasing an additional 44,748 shares during the last quarter. 71.23% of the stock is owned by hedge funds and other institutional investors.
CryoLife, Inc, together with its subsidiaries, manufactures, processes, and distributes medical devices and implantable human tissues for use in cardiac and vascular surgeries worldwide. The company operates in two segments, Medical Devices and Preservation Services. It offers BioGlue, an agent for cross-linking proteins for cardiac, vascular, pulmonary, and general surgical applications; On-X mechanical heart valves for aortic and mitral indications; cardiac preservation services; PhotoFix, a bovine pericardial patch for use in cardiac and vascular repairing activities; and PerClot, an absorbable powdered hemostat for use in surgical procedures, including cardiac, vascular, orthopedic, neurological, gynecological, ENT, and trauma surgeries.
Featured Story: Trading Options- What is a Strangle?
Receive News & Ratings for Cryolife Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryolife Inc and related companies with MarketBeat.com's FREE daily email newsletter.